Literature DB >> 1311249

Inhibition of endosomal proteolytic activity by leupeptin blocks surface expression of MHC class II molecules and their conversion to SDS resistance alpha beta heterodimers in endosomes.

J J Neefjes1, H L Ploegh.   

Abstract

The biosynthesis of MHC Class II molecules starts with the assembly of the alpha and beta subunits and the invariant chain. Intracellular transport of Class II molecules was followed in pulse-chase experiments of a human Epstein-Barr virus-transformed B lymphoblastoid cell line. Entry of Class II molecules into the endocytotic pathway and their cell surface appearance were monitored using neuraminidase as a fluid endocytotic marker and as a surface probe, respectively. In the course of intracellular transport, the Class II associated invariant chain is removed by proteases located in the endosomal pathway. Here, we show that leupeptin inhibits not only invariant chain breakdown, but also surface deposition of newly synthesized Class II molecules. Class II molecules display remarkable resistance to SDS at ambient temperature when occupied by peptide. We exploit this property to show that peptide binding precedes surface expression, and takes place in the course of intracellular transport through an endosomal compartment. Leupeptin blocks the conversion of Class II molecules to an SDS resistant complex.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1311249      PMCID: PMC556469          DOI: 10.1002/j.1460-2075.1992.tb05069.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  36 in total

1.  Association of class I major histocompatibility heavy and light chains induced by viral peptides.

Authors:  A Townsend; C Ohlén; J Bastin; H G Ljunggren; L Foster; K Kärre
Journal:  Nature       Date:  1989-08-10       Impact factor: 49.962

2.  Isolation of an endogenously processed immunodominant viral peptide from the class I H-2Kb molecule.

Authors:  G M Van Bleek; S G Nathenson
Journal:  Nature       Date:  1990-11-15       Impact factor: 49.962

3.  A role for peptide in determining MHC class II structure.

Authors:  S Sadegh-Nasseri; R N Germain
Journal:  Nature       Date:  1991-09-12       Impact factor: 49.962

4.  Human B cells alloantigens; separation from other membrane molecules by affinity chromatography.

Authors:  P Cresswell
Journal:  Eur J Immunol       Date:  1977-09       Impact factor: 5.532

5.  Purification of HLA-linked B lymphocyte alloantigens in immunologically active form by preparative sodium dodecyl sulfate-gel electrophoresis and studies on their subunit association.

Authors:  T A Springer; J F Kaufman; L A Siddoway; D L Mann; J L Strominger
Journal:  J Biol Chem       Date:  1977-09-10       Impact factor: 5.157

6.  Characterization of a naturally processed MHC class II-restricted T-cell determinant of hen egg lysozyme.

Authors:  S Demotz; H M Grey; E Appella; A Sette
Journal:  Nature       Date:  1989-12-07       Impact factor: 49.962

Review 7.  Antigen presentation pathways to class I and class II MHC-restricted T lymphocytes.

Authors:  T J Braciale; L A Morrison; M T Sweetser; J Sambrook; M J Gething; V L Braciale
Journal:  Immunol Rev       Date:  1987-08       Impact factor: 12.988

8.  Inhibition by leupeptin and antipain of the intracellular proteolysis of Ii.

Authors:  Q V Nguyen; W Knapp; R E Humphreys
Journal:  Hum Immunol       Date:  1989-03       Impact factor: 2.850

9.  Use of a monoclonal antibody (W6/32) in structural studies of HLA-A,B,C, antigens.

Authors:  P Parham; C J Barnstable; W F Bodmer
Journal:  J Immunol       Date:  1979-07       Impact factor: 5.422

10.  Isolation and characterization of human B cell alloantigens.

Authors:  R J Billing; M Safani; P Peterson
Journal:  J Immunol       Date:  1976-11       Impact factor: 5.422

View more
  53 in total

1.  Interference with T cell receptor-HLA-DR interactions by Epstein-Barr virus gp42 results in reduced T helper cell recognition.

Authors:  Maaike E Ressing; Daphne van Leeuwen; Frank A W Verreck; Raquel Gomez; Bianca Heemskerk; Mireille Toebes; Maureen M Mullen; Theodore S Jardetzky; Richard Longnecker; Marco W Schilham; Tom H M Ottenhoff; Jacques Neefjes; Ton N Schumacher; Lindsey M Hutt-Fletcher; Emmanuel J H J Wiertz
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-22       Impact factor: 11.205

Review 2.  Beyond the classical: influenza virus and the elucidation of alternative MHC class II-restricted antigen processing pathways.

Authors:  Laurence C Eisenlohr; Nancy Luckashenak; Sebastien Apcher; Michael A Miller; Gomathinayagam Sinnathamby
Journal:  Immunol Res       Date:  2011-12       Impact factor: 2.829

3.  HLA-DP, HLA-DQ, and HLA-DR have different requirements for invariant chain and HLA-DM.

Authors:  Marcel van Lith; Rosanna M McEwen-Smith; Adam M Benham
Journal:  J Biol Chem       Date:  2010-10-19       Impact factor: 5.157

4.  Epstein-Barr virus gp42 is posttranslationally modified to produce soluble gp42 that mediates HLA class II immune evasion.

Authors:  Maaike E Ressing; Daphne van Leeuwen; Frank A W Verreck; Sinéad Keating; Raquel Gomez; Kees L M C Franken; Tom H M Ottenhoff; Melanie Spriggs; Ton N Schumacher; Lindsey M Hutt-Fletcher; Martin Rowe; Emmanuel J H J Wiertz
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 5.  MHC class II molecules on the move for successful antigen presentation.

Authors:  Nuno Rocha; Jacques Neefjes
Journal:  EMBO J       Date:  2007-11-29       Impact factor: 11.598

Review 6.  MHC class II antigen presentation by dendritic cells regulated through endosomal sorting.

Authors:  Toine ten Broeke; Richard Wubbolts; Willem Stoorvogel
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-12-01       Impact factor: 10.005

Review 7.  Molecular chaperones in the processing and presentation of antigen to helper T cells.

Authors:  S K Pierce
Journal:  Experientia       Date:  1994-11-30

8.  Cathepsins B and D are dispensable for major histocompatibility complex class II-mediated antigen presentation.

Authors:  J Deussing; W Roth; P Saftig; C Peters; H L Ploegh; J A Villadangos
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-14       Impact factor: 11.205

9.  Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity.

Authors:  Kaoru Saegusa; Naozumi Ishimaru; Kumiko Yanagi; Rieko Arakaki; Kouichi Ogawa; Ichiro Saito; Nobuhiko Katunuma; Yoshio Hayashi
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

10.  Quantifying cathepsin S activity in antigen presenting cells using a novel specific substrate.

Authors:  Nicolas Lützner; Hubert Kalbacher
Journal:  J Biol Chem       Date:  2008-10-28       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.